Heron Therapeutics shares surge 12.97% premarket driven by insider buying and institutional investments in Q3.

Heron Therapeutics surged 12.97% in premarket trading, driven by strategic capital restructuring and insider buying. The company announced a comprehensive capital restructuring on August 8, 2025, to extend its maturity profile and support growth, signaling improved financial stability. Additionally, insider purchases of 2.39 million shares by major shareholders and directors on August 14 demonstrated strong confidence in the company’s long-term prospects. These developments likely offset earlier mixed Q3 results and analyst downgrades, as investors focused on the restructuring’s potential to strengthen Heron’s balance sheet and operational flexibility. The alignment of insider activity with management’s strategic initiatives further reinforced optimism ahead of the premarket rally.